ACE-I and ARBs in early diabetic nephropathy - PubMed (original) (raw)
Clinical Trial
doi: 10.3317/jraas.2002.048.
Affiliations
- PMID: 12584670
- DOI: 10.3317/jraas.2002.048
Free article
Clinical Trial
ACE-I and ARBs in early diabetic nephropathy
Michael Mauer et al. J Renin Angiotensin Aldosterone Syst. 2002 Dec.
Free article
Abstract
Introduction: Antihypertensive treatment of patients with clinical manifestations of diabetic nephropathy, and especially, renin-angiotensin system (RAS) inhibition, slows, but may not fully arrest progression towards end-stage renal disease. Studies using hard endpoints such as doubling of serum creatinine, dialysis, or death that are initiated before emergence of any renal functional abnormalities in diabetes, would be of impractical length and size. We therefore undertook a primary prevention study (The Renin-Angiotensin System Study or RASS) to determine if inhibition of the RAS could slow the development of a key diabetic glomerulopathy structural endpoint, increase in mesangial fractional volume (Vv[Mes/glom]).
Methods: This is a parallel group, double-blind, placebo-controlled trial with 285 patients with Type 1 diabetes mellitus (95 per group) randomised to receive the angiotensin-converting enzyme inhibitor, enalapril, the angiotensin II receptor blocker, losartan, or placebo. All patients are normotensive, normoalbuminuric and have normal or increased glomerular filtration rates at study entry. The study is based on primary endpoint of change in Vv(Mes/glom) from baseline to the five-year renal biopsy, with baseline and interval measures of albumin excretion rate, glomerular filtration rate, blood pressure, and glycaemia. Baseline, mid-point, and five-year retinal fundus photography are also performed.
Results: One thousand and sixty-five patients were interviewed, 707 refused participation and 73 were excluded. The target of 285 subjects were randomised and their clinical and demographic characteristics are described. Biopsy complications occurred in 17 (6%), only one of which required hospitalisation. There were no permanent biopsy-related sequelae.
Conclusions: Renal structural variables are reasonable surrogate endpoints for studies of progression of early diabetic nephropathy. Although requiring substantial recruitment effort, diabetic nephropathy primary prevention trials based on change in renal structure are feasible.
Similar articles
- [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
Parving HH, Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Parving HH, et al. Ugeskr Laeger. 2001 Oct 1;163(40):5514-9. Ugeskr Laeger. 2001. PMID: 11601117 Clinical Trial. Danish. - Advances in the treatment of diabetic renal disease: focus on losartan.
Rayner B. Rayner B. Curr Med Res Opin. 2004 Mar;20(3):333-40. doi: 10.1185/030079903125003107. Curr Med Res Opin. 2004. PMID: 15025842 Review. - Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
Sasaki M, Uehara S, Ohta H, Taguchi K, Kemi M, Nishikibe M, Matsumoto H. Sasaki M, et al. Life Sci. 2004 Jul 2;75(7):869-80. doi: 10.1016/j.lfs.2004.01.022. Life Sci. 2004. PMID: 15183078 - Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study.
Ravid M, Lang R, Rachmani R, Lishner M. Ravid M, et al. Arch Intern Med. 1996 Feb 12;156(3):286-9. Arch Intern Med. 1996. PMID: 8572838 Clinical Trial. - Losartan in diabetic nephropathy.
Perico N, Ruggenenti P, Remuzzi G. Perico N, et al. Expert Rev Cardiovasc Ther. 2004 Jul;2(4):473-83. doi: 10.1586/14779072.2.4.473. Expert Rev Cardiovasc Ther. 2004. PMID: 15225108 Review.
Cited by
- Blood pressure control for diabetic retinopathy.
Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Do DV, et al. Cochrane Database Syst Rev. 2015 Jan 31;1:CD006127. doi: 10.1002/14651858.CD006127.pub2. Cochrane Database Syst Rev. 2015. PMID: 25637717 Free PMC article. Updated. Review. - The relationship of retinal vessel diameter to changes in diabetic nephropathy structural variables in patients with type 1 diabetes.
Klein R, Knudtson MD, Klein BE, Zinman B, Gardiner R, Suissa S, Sinaiko AR, Donnelly SM, Goodyer P, Strand T, Mauer M. Klein R, et al. Diabetologia. 2010 Aug;53(8):1638-46. doi: 10.1007/s00125-010-1763-3. Epub 2010 May 1. Diabetologia. 2010. PMID: 20437026 Free PMC article. Clinical Trial. - Adherence and renal biopsy feasibility in the Renin Angiotensin-System Study (RASS) primary prevention diabetes trial.
Robiner WN, Strand TD, Mauer M; Renin Angiotensin System Study (RASS) Group. Robiner WN, et al. Diabetes Res Clin Pract. 2013 Oct;102(1):25-34. doi: 10.1016/j.diabres.2013.06.004. Epub 2013 Sep 17. Diabetes Res Clin Pract. 2013. PMID: 24050942 Free PMC article. Clinical Trial. - The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.
Wright JW, Harding JW. Wright JW, et al. Pflugers Arch. 2013 Jan;465(1):133-51. doi: 10.1007/s00424-012-1102-2. Epub 2012 Apr 26. Pflugers Arch. 2013. PMID: 22535332 Review. - Renal and retinal effects of enalapril and losartan in type 1 diabetes.
Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R. Mauer M, et al. N Engl J Med. 2009 Jul 2;361(1):40-51. doi: 10.1056/NEJMoa0808400. N Engl J Med. 2009. PMID: 19571282 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous